Top

Published in:

01-10-2010 | Research Paper

CD133⁺ single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential

Authors: Guangqiu Li, Chao Liu, Jian Yuan, Xiaoqin Xiao, Na Tang, Junmei Hao, Hongwei Wang, Xiuwu Bian, Yongjian Deng, Yanqing Ding

Published in: Clinical & Experimental Metastasis | Issue 7/2010

Abstract

Single cell progenies (SCPs) inherit biological properties from their isogenetic mother cells. If a single cancer cell can give rise to progenies, which can be passaged sustainably in vitro and produce tumor in xenotransplantation, the cell should be cancer initiating cell. CD133 (Prominin-1, Prom1) is the marker of human colorectal cancer (CRC) stem cells and probably a marker of metastatic cancer stem cells (CSCs). Thirty-three SCPs of CRC cell line SW480 were isolated by limited dilution methods, thirty of which are CD133 positive and three negative. All of the CD133⁺ SCPs are tumorigenic, and the subcutaneous tumors expanded rapidly, while only 1 of 3 CD133⁻ SCPs developed a minimal tumor in nude mice. Orthotopic transplantation experiments showed that CD133⁺ SCPs possessed heterogeneity in intestinal wall invasion, lymph node and liver metastases. CD133⁺ SCPs varied in cell growth, invasive ability, epithelial-mesenchymal-transition and expression of CSCs markers (CD133, CD44, and CXCR4) associated with metastatic potential. CD133⁻ SCPs did not produce secondary transplanted tumor, intestinal invasion and metastasis. The results indicated CD133⁺ subpopulation of SW480 SCPs bear heterogeneous invasive and metastatic ability, and CRC-CSCs might be a heterogeous subpopulation.

Nelson H, Petrelli N, Carlin A et al (2001) Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93(8):583–596CrossRefPubMed

O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96(19):1420–1425CrossRefPubMed

Miller SJ, Lavker RM, Sun TT (2005) Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 1756(1):25–52PubMed

Al-Hajj M, Becker MW, Wicha M et al (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14(1):43–47CrossRefPubMed

Brabletz T, Jung A, Spaderna S et al (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744–749CrossRefPubMed

O’Brien CA, Pollett A, Gallinger S et al (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106–110CrossRefPubMed

Ricci-Vitiani L, Lombardi DG, Pilozzi E et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123):111–115CrossRefPubMed

Dalerba P, Dylla SJ, Park IK et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104(24):10158–10163CrossRefPubMed

Li CY, Li BX, Liang Y et al (2009) Higher percentage of CD133⁺ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 7:56CrossRefPubMed

10.

Choi D, Lee HW, Hur KY et al (2009) Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 15(18):2258–2264CrossRefPubMed

11.

Horst D, Scheel SK, Liebmann S et al (2009) The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 219(4):427–434CrossRefPubMed

12.

Wang Q, Chen ZG, Du CZ et al (2009) Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology 55(3):284–293CrossRefPubMed

13.

Horst D, Kriegl L, Engel J et al (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99(8):1285–1289CrossRefPubMed

14.

Horst D, Kriegl L, Engel J et al (2009) Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 27(8):844–850CrossRefPubMed

15.

Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265–273CrossRefPubMed

16.

Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715CrossRefPubMed

17.

Hugo H, Ackland ML, Blick T et al (2007) Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 213(2):374–383CrossRefPubMed

18.

Joyce T, Cantarella D, Isella C et al (2009) A molecular signature for epithelial to mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis. Clin Exp Metastasis 26(6):569–587CrossRefPubMed

19.

Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828PubMed

20.

Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401CrossRefPubMed

21.

Collins AT, Berry PA, Hyde C et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65(23):10946–10951CrossRefPubMed

22.

Vander Griend DJ, Karthaus WL, Dalrymple S et al (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68(23):9703–9711CrossRefPubMed

23.

Yin S, Li J, Hu C et al (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120(7):1444–1450CrossRefPubMed

24.

Hermann PC, Huber SL, Herrler T et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323CrossRefPubMed

25.

Eramo A, Lotti F, Sette G et al (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15(3):504–514CrossRefPubMed

26.

Cox CV, Diamanti P, Evely RS et al (2009) Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood 113(14):3287–3296CrossRefPubMed

27.

Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26(12):3008–3017CrossRefPubMed

28.

Shmelkov SV, Butler JM, Hooper AT et al (2008) CD133 expression is not restricted to stem cells, and both CD133⁺ and CD133⁻ metastatic colon cancer cells initiate tumors. J Clin Invest 118(6):2111–2120PubMed

29.

LaBarge MA, Bissell MJ (2008) Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 118(6):2021–2024PubMed

30.

Liu L, Zhang Q, Zhang Y et al (2006) Lentivirus-mediated silencing of Tiam1 gene influences multiple functions of a human colorectal cancer cell line. Neoplasia 8(11):917–924CrossRefPubMed

31.

Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456(7222):593–598CrossRefPubMed

32.

Hao JM, Chen JZ, Sui HM et al (2010) A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol 220(4):475–489PubMed

33.

Haraguchi N, Ohkuma M, Sakashita H et al (2008) CD133⁺ CD44⁺ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 15(10):2927–2933CrossRefPubMed

34.

Reya T, Morrison SJ, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111CrossRefPubMed

35.

Snippert HJ, van Es JH, van den Born M, et al (2009) Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine. Gastroenterology 136(7):2187–2194 e1

36.

Yoshikawa S, Zen Y, Fujii T et al (2009) Characterization of CD133+ parenchymal cells in the liver: histology and culture. World J Gastroenterol 15(39):4896–4906CrossRefPubMed

37.

Beier D, Hau P, Proescholdt M et al (2007) CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67(9):4010–4015CrossRefPubMed

38.

Lottaz C, Beier D, Meyer K et al (2010) Transcriptional profiles of CD133⁺ and CD133⁻ glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70(5):2030–2040CrossRefPubMed

39.

Meng X, Li M, Wang X et al (2009) Both CD133⁺ and CD133⁻ subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci 100(6):1040–1046CrossRefPubMed

40.

Pece S, Tosoni D, Confalonieri S et al (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1):62–73CrossRefPubMed

41.

Barker N, van Es JH, Kuipers J et al (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449(7165):1003–1007CrossRefPubMed

42.

Sato T, Vries RG, Snippert HJ et al (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459(7244):262–265CrossRefPubMed

43.

Zhu L, Gibson P, Currle DS et al (2009) Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457(7229):603–607CrossRefPubMed

44.

Morimoto-Tomita M, Ohashi Y, Matsubara A et al (2005) Mouse colon carcinoma cells established for high incidence of experimental hepatic metastasis exhibit accelerated and anchorage-independent growth. Clin Exp Metastasis 22(6):513–521CrossRefPubMed

Title: CD133+ single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential
Authors: Guangqiu Li
Chao Liu
Jian Yuan
Xiaoqin Xiao
Na Tang
Junmei Hao
Hongwei Wang
Xiuwu Bian
Yongjian Deng
Yanqing Ding
Publication date: 01-10-2010
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 7/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-010-9341-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2010

Oleic acid promotes MMP-9 secretion and invasion in breast cancer cells

Cold shock domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis in a mouse model of squamous cell carcinoma

Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway

Individual and combined soy isoflavones exert differential effects on metastatic cancer progression

Repression of Lim only protein 4-activated transcription inhibits proliferation and induces apoptosis of normal mammary epithelial cells and breast cancer cells

Alteration in protein expression in estrogen receptor alpha-negative human breast cancer tissues indicates a malignant and metastatic phenotype

Keynote webinar | Spotlight on antibody–drug conjugates in cancer